(VIANEWS) – CARMILA (CARM.PA), UCB (UCB.BR), AIR LIQUIDE (AI.PA) are the highest payout ratio stocks on this list.
Here’s the data we’ve collected of stocks with a high payout ratio up until now. The payout ratio in itself isn’t a guarantee of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.
1. CARMILA (CARM.PA)
315.79% Payout Ratio
As the third-largest listed owner of commercial property in Europe, Carmila was founded by Carrefour and large institutional investors in order to enhance the value of shopping centres adjoining Carrefour hypermarkets in France, Spain and Italy. At 31 December 2023, its portfolio was valued at €5.9 billion and is made up of 201 shopping centres, with leading positions in their catchment areas. Carmila is listed on Euronext-Paris Compartment A under the symbol CARM. It benefits from the tax regime for French real estate investment trusts (“SIIC”). Carmila has been a member of the SBF 120 since 20 June 2022.
Earnings Per Share
As for profitability, CARMILA has a trailing twelve months EPS of €0.02.
PE Ratio
CARMILA has a trailing twelve months price to earnings ratio of 806. Meaning, the purchaser of the share is investing €806 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1.6%.
Volume
Today’s last reported volume for CARMILA is 40139 which is 1.99% below its average volume of 40957.
More news about CARMILA.
2. UCB (UCB.BR)
111.48% Payout Ratio
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.21.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 136.61. Meaning, the purchaser of the share is investing €136.61 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 2.67%.
Moving Average
UCB’s value is higher than its 50-day moving average of €159.71 and way above its 200-day moving average of €125.72.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10.8%, now sitting on 5.45B for the twelve trailing months.
More news about UCB.
3. AIR LIQUIDE (AI.PA)
50.26% Payout Ratio
L'Air Liquide S.A. provides gases, technologies, and services for the industrial and health sectors in Europe, the Americas, the Asia Pacific, the Middle East, and Africa. It operates in Gas & Services, Engineering & Construction, and Global Markets & Technologies segments. The Gas & Services segment comprises large industries business, which offers gas and energy solutions including oxygen, nitrogen, argon, hydrogen, and carbon monoxide, as well as operates cogeneration plants to supply steam and electricity to metals, chemicals, refining, and energy industries; and industrial merchant business line provides industrial gases, equipment, hardgoods, and associated services to materials and energy, automotive and manufacturing, food and pharmaceuticals, technology and research, and craftsmen and retail sectors. This segment also includes healthcare business, which provides medical gases, home healthcare services, medical equipment, and specialty ingredient to patients, healthcare professionals, and hospitals; and electronic business supply carrier gases, electronic specialty and advanced materials, equipment and installation, and service to semiconductor, flat panel, and photovoltaic markets. The Engineering & Construction segment designs, develops, and builds industrial gas production plants to third parties; and design and manufacture plants in traditional, renewable and alternative energy sectors. The Global Markets & Technologies segment delivers technological solutions, such as molecules, equipment, and services to energy transition and deep technology. This segment also invests in and operates biomethane production units; designs hydrogen refueling stations; and supplies gases for the offshore oil and gas platforms, offshore wind turbines, and cryogenic transportation by sea. L'Air Liquide S.A. was incorporated in 1902 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, AIR LIQUIDE has a trailing twelve months EPS of €5.26.
PE Ratio
AIR LIQUIDE has a trailing twelve months price to earnings ratio of 31.92. Meaning, the purchaser of the share is investing €31.92 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.83%.
Yearly Top and Bottom Value
AIR LIQUIDE’s stock is valued at €167.90 at 12:10 EST, way below its 52-week high of €197.42 and way higher than its 52-week low of €151.36.
More news about AIR LIQUIDE.
4. MANITOU BF (MTU.PA)
31.69% Payout Ratio
Manitou BF SA, together with its subsidiaries, engages in the development, manufacture, and provision of equipment and services worldwide. It operates in two divisions, Product, and Services and Solutions. The company offers material handling, access, and earthmoving equipment, including rough-terrain fixed, rotating, and heavy-duty telehandlers; rough-terrain, semi-industrial, and industrial forklift trucks; skid-steer, articulated, backhoe, and track loaders; aerial work platforms; and truck-mounted forklifts, as well as warehousing equipment. It also provides attachments, such as buckets, clamps, cups, fork handling solutions, forks and grapples, jibs, work platforms, skips, sweepers and cleaners, winches, mining accessories, and miscellaneous attachments, as well as backrest, carriage, and interface references. In addition, the company offers value added services comprising technical training, new or refurbished spare parts, after-sales service, machine connectivity, fleet management, financing solutions, maintenance and warranty extension contracts, rent-to-rent leases, full-service contracts, recovery, repair, and resale of used equipment. The company offers its products through a network of dealers under the Manitou, Gehl, and Mustang by Manitou brands in agriculture, construction, industry, aeronautics, defense, environment, mining and quarries, and oil and gas markets. Manitou BF SA was incorporated in 1954 and is headquartered in Ancenis, France.
Earnings Per Share
As for profitability, MANITOU BF has a trailing twelve months EPS of €3.75.
PE Ratio
MANITOU BF has a trailing twelve months price to earnings ratio of 6.76. Meaning, the purchaser of the share is investing €6.76 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.56%.
Yearly Top and Bottom Value
MANITOU BF’s stock is valued at €25.35 at 12:10 EST, way below its 52-week high of €29.00 and way above its 52-week low of €16.32.
Revenue Growth
Year-on-year quarterly revenue growth grew by 0.4%, now sitting on 2.88B for the twelve trailing months.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jun 17, 2024, the estimated forward annual dividend rate is 1.35 and the estimated forward annual dividend yield is 7.48%.
More news about MANITOU BF.
1. 1 (1)
1% Payout Ratio
1
Earnings Per Share
As for profitability, 1 has a trailing twelve months EPS of €1.
PE Ratio
1 has a trailing twelve months price to earnings ratio of 1. Meaning, the purchaser of the share is investing €1 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 1%.
Sales Growth
1’s sales growth is 1% for the ongoing quarter and 1% for the next.
More news about 1.
